Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy

Annals of Clinical Psychiatry

Volumn 13, Issue 1, 2001, Pages 31-41

  Goodnick, P J ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressants; Diabetes mellitus; Fluoxetine; Neuropathy; Sertraline; Tricyclic antidepressants

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CATECHOLAMINE; CITALOPRAM; CLOMIFENE; CLOMIPRAMINE; DESIPRAMINE; FLUOXETINE; FLUPHENAZINE; HEMOGLOBIN A1C; IMIPRAMINE; MAPROTILINE; MIANSERIN; NEFAZODONE; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; PAROXETINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

CLINICAL TRIAL; COGNITION; COMORBIDITY; DEPRESSION; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC NEUROPATHY; DOSE RESPONSE; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; HEMOGLOBIN DETERMINATION; HUMAN; INSULIN RELEASE; INSULIN SENSITIVITY; PREVALENCE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REVIEW; SEROTONINERGIC SYSTEM; SLEEP; WEIGHT REDUCTION;

ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BLOOD GLUCOSE; CLINICAL TRIALS; COGNITION; COMORBIDITY; DEPRESSIVE DISORDER; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETIC NEUROPATHIES; DRUG INTERACTIONS; FLUOXETINE; HUMANS; SLEEP; WEIGHT GAIN;

EID: 0034931483     PISSN: 10401237     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009012815127     Document Type: Review

References (83)

1. Prevalence of depression in adults with diabetes: An epidemiologic evaluation
2. Burden of illness, metabolic control, and complications in relation to depressive symptoms in IDDM patients
3. Depression and risk for onset of type II diabetes
4. Depressive symptoms and occurrence of type 2 diabetes among Japanese men
5. Depression and the reporting of diabetes symptoms
6. Cognitive and affective disorders in elderly diabetics
7. Psychiatric illness and diabetes mellitus. Relationship of symptoms to glucose control
8. Depression and diabetes
9. The association of lifetime pschiatric illness and increased retinopathy in patients with type I diabetes mellitus
10. Glycemic control and major depression in patients with type 1 and type 2 diabetes mellitus
11. Insulin resistance in patients with depression and its changes in the clinical course of depression: A report on three cases using the minimal model analysis
12. Hormonal effects of norepinephrine on acute glucose disposal in humans: A minimal model analysis
13. Monoamine in the pancreatic islets of the mouse
14. The hypoglycemic effect of 5-hydroxytrytophan
15. Effects of inhibitors to 5-hydroxytryptamine uptake on plasma glucose and their interactions with 5-hydroxytryptophan in producing hypoglycemia in mice
16. Further studies on the effects of 5-hydroxytryptophan on plasma glucose and insulin in the mouse
17. Influence of melatonin and serotonin on glucose-stimulated insulin release from perifused rat pancreatic islets in vitro
18. Melatonin and serotonin regulate the release of insulin-like growth factor-I, oxytocin, and progesterone by cultured granolosa cells
19. Serotonin: A novel regulator of glucose transport in rat skeletal muscle
20. Fenfluramine increases insulin action in patients with NIDDM
21. Improvement of insulin-induced glucose disposal in obese patients with NIDDM after 1 week treatment with d-fenfluramine
22. Effects of dexfenfluramine on free fatty acid turnover and oxidation in obese patients with type 2 diabetes mellitus
23. Obese patients with type 2 diabetes poorly controlled by insulin and metformin: Effects of adjunctive dexfenfluramine therapy on glycemic control
24. Pharmacology of antidepressants - Characteristics of the ideal drug
25. Use of imipramine in diabetics
26. Different effects of the antidepressant drugs imipramine, maprotiline, and bupropion on insulin secretion from mouse pancreatic islets
27. Effect of some antidepressants on glycaemia and insulin levels of normoglycaemic and alloxan-induced hyperglycaemic mice
28. Effects of nortriptyline on depression and glycemic control in diabetes: Results of a double-blind, placebo-controlled trial
29. Hypoglycemia associated with maprotiline in a patient with type I diabetes
30. Bupropion and sexual function: A placebo-controlled prospective study on diabetic men with erectile dysfunction
31. On the hyperglycemic effect of dopa and dopamine
32. Inhibition of insulin release by substrates and inhibitors of monoamine oxidase
33. Inhibition of pancreatic islet monoamine oxidase by adrenergic antagonists and ethanol
34. Glucose uptake during centrally induced stress is insulin independent and enhanced by adrenergic blockade
35. The effect of norepinephrine on insulin secretion and glucose effectiveness in non-insulin-dependent diabetes
36. TRP64ARG beta 3-adrenergic receptor and obesity in Mexican Americans
37. Efficacy of desipramine in painful diabetic neuropathy: A placebo-controlled trial
38. Nefazodone-induced hypoglycemia
39. Pathophysiology and treatment of diabetic neuropathy
40. Fluoxetine increases insulin action in obese nondiabetic and in obese non-insulin-dependent diabetic individuals
41. Fluoxetine treatment of the obese diabetic
42. Fluoxetine in the treatment of obese type 2 diabetic patients
43. A study of fluoxetine in obese elderly patients with type 2 diabetes
44. Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss
45. Sertraline in coexisting major depression and diabetes mellitus
46. Fluoxetine for depression in diabetes
47. New pharmacological approaches to therapy of NIDDM
48. Hypotensive collapse and hypoglycemia after mebanazine, a monoamine oxidase inhibitor
49. Depression, glucose tolerance, peripheral glucose uptake, and their alterations under the influence of antidepressive drugs of the hydrazine type
50. Potentiation of insulin hypoglycemia by MAOI antidepressant drugs
51. Adverse reactions to monoamine oxidase inhibitors: I: A comparative study
52. Antidepressant drug side effects
53. The effects of the serotonin reuptake inhibitor, fluoxetine, on weight loss, glycemic control, and lipid levels in non-insulin dependent diabetes mellitus
54. Antidepressant efficacy of sertraline: A double-blind, placebo- and amitriptyline-controlled multicenter comparison study in out-patients with major depression
55. The effect of desipramine on body weight in depression
56. Amitriptyline, weight gain, and carbohydrate cravings: A side effect
57. Amitriptyline and weight gain: A biochemical and endocrinological study
58. Changes occurring in appetite and weight during short-term antidepressant treatment
59. Weight gain: A side effect of tricyclic antidepressants
60. Appetite an food preference in depression: Effects of imipramine treatment
61. Geriatric sweet tooth
62. Bupropion-induced carbohydrate cravings
63. Effect of bupropion on chocolate cravings
64. Weight gain associated with SSRIs
65. Diagnosis and management of diabetic neuropathy
66. Diabetes mellitus and its degenerative complications: A prospective study of 4400 patients observed
67. Nortriptyline and fluphenazine in the symptomatic treatment of diabetic neuropathy: A double blind cross over study
68. Imipramine therapy of painful diabetic neuropathy
69. Imipramine treatment in diabetic neuropathy: Relief of subjective symptoms without changes in peripheral and autonomic nerve function
70. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood
71. Clomipramine vs. desipramine vs placebo in the treatment of diabetic neuropathy symptoms: A double-blind cross-over study
72. Effects of desipramine, amitriptyline, and fluoxetine in diabetic neuropathy
73. Concentration-response relationship in paroxetine treatment of diabetic neuropathy symptoms: A patient-blinded dose-escalation study
74. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms
75. The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy
76. Sertraline in diabetic neuropathy
77. Sertraline in diabetic neuropathy: Response and biology
78. Lack of effect of mianserin on the symptoms of diabetic neuropathy
79. Efficacy of bupropion SR in neuropathic pain: An open-label study
80. Diabetic neuropathic pain management with venlafaxine extended release
81. Nefazodone in diabetic neuropathy: Response and biology
82. Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated 5-HT2c receptor gene